The team

Senior pharmacometrics and clinical pharmacology

Experience
15+ years of senior experience in quantitative clinical pharmacology behind every program, across big pharma and leading CROs
Regulatory submissions
10+ supported since 2022, with FDA, EMA and PMDA interactions
Programs
30+ since 2022, across peptides, monoclonal antibodies, ADCs, ASOs, small molecules, complex generics and biosimilars

Our team has led DMPK and translational modeling in big pharma, from candidate selection through IND-enabling studies, and directed pharmacometrics for early clinical development across global portfolios: model-based dose selection from first-in-human to Phase 2, the modeling sections of IND submissions, and the design of Phase 1 SAD/MAD, food-effect, DDI and bioequivalence studies.

At leading CROs, we have been scientific leads for PK deliverables across 20+ client programs, reviewed and signed off analyses in GxP settings, and managed teams of PK scientists, modelers and statistical programmers.

The work spans NCA, population PK/PD, exposure-response, PBPK, QSP and bioequivalence, in NONMEM, Monolix, R, Phoenix WinNonlin, PK-Sim and GastroPlus. pmxstudio.ai puts that experience directly on your program, at a fixed price and on a guaranteed date.

Oncology, immunology, rare and metabolic disease, infectious disease and neuroscience. From IND briefing documents to Modules 5.3.3 and 5.3.4 of NDAs, BLAs and MAAs.

On the first call, we introduce the people who would work on your program, with their CVs, under NDA.

Why a studio

Pharmacometrics sold by the hour rewards more hours and adds layers between you and the modeler. We sell a defined piece of evidence at a fixed price, which rewards finishing it well and on time.

Our own AI agents, running on our own servers, carry the repeatable work. That keeps the senior experts on the science, and the overhead low enough to fix prices and guarantee dates.

pmxstudio.ai is a Quantmetrics Ltd. company. Quantmetrics Ltd. is the contracting entity for every project, and its registration details are set out in the MSA.

The network

  • Clinical and medical · clinical input on indication, endpoints and safety
  • Biostatistics · trial design and statistical analysis
  • Regulatory affairs · regulatory strategy, briefing documents and publishing
  • Pharmacometrics · additional modeling capacity and continuity

Introduced by name, under the same NDA.

Talk to the person who would do the work

A fixed proposal follows within 48 hours.